411 related articles for article (PubMed ID: 30482392)
1. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Vossen ARJV; van Doorn MBA; van der Zee HH; Prens EP
J Am Acad Dermatol; 2019 Jan; 80(1):80-88. PubMed ID: 30482392
[TBL] [Abstract][Full Text] [Related]
2. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
6. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
8. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
Weber P; Seyed Jafari SM; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2017 Jun; 76(6):1189-1191. PubMed ID: 28522043
[No Abstract] [Full Text] [Related]
9. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
11. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Genovese MC; Jarosova K; Cieślak D; Alper J; Kivitz A; Hough DR; Maes P; Pineda L; Chen M; Zaidi F
Arthritis Rheumatol; 2015 Jul; 67(7):1703-10. PubMed ID: 25779750
[TBL] [Abstract][Full Text] [Related]
12. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB; Jemec GBE; Alavi A; Reguiai Z; Gottlieb AB; Bechara FG; Paul C; Giamarellos Bourboulis EJ; Villani AP; Schwinn A; Ruëff F; Pillay Ramaya L; Reich A; Lobo I; Sinclair R; Passeron T; Martorell A; Mendes-Bastos P; Kokolakis G; Becherel PA; Wozniak MB; Martinez AL; Wei X; Uhlmann L; Passera A; Keefe D; Martin R; Field C; Chen L; Vandemeulebroecke M; Ravichandran S; Muscianisi E
Lancet; 2023 Mar; 401(10378):747-761. PubMed ID: 36746171
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
[TBL] [Abstract][Full Text] [Related]
16. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
17. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
